Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...
Biogen (NASDAQ:BIIB) Earns Neutral Rating from Analysts at Citigroup
Citigroup initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued on Thursday, MarketBeat ...
bovnews9m
Why Did Wolfe Research Give Biogen Inc (BIIB) Stock Peer Perform Rating?
On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...
Fintel on MSN1d
Citigroup Initiates Coverage of Biogen (BIIB) with Neutral Recommendation
Fintel reports that on November 14, 2024, Citigroup initiated coverage of Biogen (NasdaqGS:BIIB) with a Neutral ...
Los Angeles Capital Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB)
Los Angeles Capital Management LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the third ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Benzinga.com1d
Biogen Unusual Options Activity
Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ...